Green light for Immunovaccine’s combination trial
December 2017

HALIFAX, Nova Scotia—In November, Immunovaccine Inc. reported that it had received Sunnybrook Research Institute regulatory clearance from Health Canada to start recruiting for a Phase 2 clinical study of a triple-combination immunotherapy in patients with measurable or recurrent diffuse large B cell lymphoma. The study will assess the safety and efficacy of DPX-Survivac, Immunovaccine’s lead product candidate, in combination with Merck’s pembrolizumab and low-dose cyclophosphamide.
Frederic Ors, CEO of Immunovaccine, said that “Despite promising results observed in the treatment of DLBCL with cutting-edge monotherapies like checkpoint inhibitors, a significant number of patients still do not respond to treatment … Through complementary mechanisms of action, we believe the combination of DPX-Survivac and pembrolizumab could amplify T cell production and infiltration to help realize the desired immune response in a broader range of patients with this type of cancer.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.